Suzhou Pengxu Pharmatech Co., Ltd.

Crystal Pharmatech Co., Ltd.

Columbia University

University of Michigan

Esteve Quimica S.a.

Crystal Pharmatech Inc.

Nitto-Denko Corporation

Peng Wang

Pixu Li

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Chaohui Yang

Yuanhua Liu

Qiang Wei

Shijun Zheng

Jeffrey T Koberstein

Isamu Kitahara

Rebecca Romero

Weiping Lin

Zhong Wang

Xiangyong Gu

Feng Pan

Masahiko Hirose

Shunsuke Noumi

Feng Gao

Craig Roger Bartels

John Ericson

Jiaoyang Li

Fei Lu

Yue Cao

Ozair Siddiqui

Makoto Kobuke

Yuji Yamashiro

Reza Farjam

Kwangjoo Lee

Wanyun Hsieh

Qianghua Jiang

Yadong Ge

Qiangqiang Du

Hailong Yang

Hui Xia

Heng Ge

The present invention provides a scalable synthesis of enantiomerically pure brivaracetam, and related derivatives.

Processes to produce brivaracetam

The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.

Processes to produce elagolix

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor. 

Processes to produce acalabrutinib

Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

Crystalline forms of lesinurad and its sodium salt

Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

Salts and co-crystals of lesinurad

Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3'-methyl-T-(pentanoyl{2&#x2033;-(tetrazol-5-ylate)biphenyl-4&#x2032;-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.

Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof

Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.

Crystalline form I of ibrutinib

Physiological imaging-defined subvolumes of tissues/disease are identified to yield spatially-defined prognostic and/or predictive indicators and/or focal therapy targets within such tissues, in particular tumors, for evaluation over time, for example, prior to and after a therapy treatment. Medical image data is analyzed to delineate subvolumes of tissue based upon multiple physiological, metabolic, and biological imaging properties, where those subvolumes are extracted and analyzed in a probabilistic manner to associate with one or more abnormal or disease phenotype conditions.

Subvolume identification for prediction of treatment outcome

The invention is directed to methods for coating monolayer films of surface-active polymers onto substrates of arbitrary shape, and molecular-based methods and processes to control the chemical and physical nature of surfaces and interfaces. The invention is also directed to methods for modifying a surface of a monolayer comprising a) coating a monolayer on a substrate, wherein the monolayer is formed by self-assembly of end-surfactant molecules, thereby positioning a photoactive functional group at the air-monolayer interface; and b) exposing the monolayer to radiation, wherein each organic group of the monolayer contains a first functionality that is not converted to a second functionality upon exposure to acid.

Methods for modifying surfaces

A method for surface micropatterning includes forming on a surface containing a first polymer a first coating containing a second polymer having first functionalities capable of being converted to second functionalities by exposure to an acid. A second coating containing a photoacid generator is formed on the first coating. The second coating containing the photoacid generator is selectively irradiated in one or more regions thereof with radiation having a spatially varying internsity pattern to generate an acid in each irradiated region of the second coating. The acid converts the first functionalities of each region of the second polymer underlying a respective irradiated region of the second coating to second functionalities. A first molecular patterned surface having one or more regions of the first functionalities and one or more regions of the second functionalities is formed.

Micropatterning of molecular surfaces via selective irradiation

Growing community of inventors

Forest Hills, NY, United States of America

Peng Wang